http://archive.nytimesn7cgmftshazwhfgzm37qxb44r64ytbb2dj3x62d2lljsciiyd.onion/dealbook.nytimesn7cgmftshazwhfgzm37qxb44r64ytbb2dj3x62d2lljsciiyd.onion/2015/02/05/a-deal-that-could-reverse-pfizers-history-of-value-destroying-acquisitions/index.html
If Hospira can inject some vigor – or even growth – into that business, the reward could be an investor-pleasing spinoff. Pfizer Bets $15 Billion on New Class of Generic Drugs By DAVID GELLES and KATIE THOMAS In its offer to buy Hospira, Pfizer is paying richly for what it believes will be a lucrative source of future revenue, drugs known as biosimilars.